Discover a new way to find and share stories you'll loveā€¦ Learn about Reading Desk

Blog Profile / In the Pipeline

Filed Under:Medical / Pharmaceutical
Posts on Regator:1653
Posts / Week:9.2
Archived Since:November 3, 2010

Blog Post Archive

Gitcher SF5 Groups Right Here

I think that several of us in medicinal chemistry have been keeping our eyes out for a chance to work in a pentafluorosulfanyl (SF5) group. I know I have - I actually have a good-sized folder on the things, and some of the intermediates as well, but I've never found the right opportunity. Show More Summary

Changing A Broken Science System

Here's a suggestion for a total reform of the graduate student/postdoc system of scientific labor and training. It's from a distinguished list of authors, and appears in a high-profile journal, and it says without any equivocation that...Show More Summary

One and Done

Matthew Herper has a good piece in Forbes on Robert Duggan and Pharmacyclics. In the course of it, we learn this interesting (and perhaps disturbing) bit of information: Second acts in the biotech business are hard: 56% of the drug firms...Show More Summary

The Latest Protein-Protein Compounds

Here's a review of protein-protein interaction "hot spots" and their application to drug discovery. There have been several overviews like this over the years. This one doesn't break much new ground, but it does provide a number of recent...Show More Summary

Professor Fukuyama's Solvent Peaks

See Arr Oh expresses some doubts about all the NMR spectral corrections we've been seeing lately: If your group focuses on "clean up your spectra" more than "purify your compounds better," that's a communications issue. If a professor with a large group sees nothing but perfect spectra all day, two thoughts should crop up: 1. Show More Summary

Novartis Gets Out of RNAi

Yesterday brought the sudden news that Novartis is pulling their RNA interference research work. The company is citing difficulties in development, and also the strategic point that not as many disease areas seem to be open to the use of the technique as they'd like. Show More Summary

Total Synthesis in Flow

Steve Ley and co-workers have published what is surely the most ambitious flow-chemistry-based total synthesis ever attempted. Natural products spirodienal A and spirangien A methyl ester are prepared with almost every step (and purification) being done in flow mode. The scheme shown will give you the idea. Show More Summary

Sweet Reason Lands On Its Face

This study has implications for many fields of science where its practitioners keep running into rumor and conspiracy theories. The authors tried several different means to increase the uptake of the MMR vaccine (information about the...Show More Summary

More on the Science Chemogenomic Signatures Paper

This will be a long one. I'm going to take another look at the Science paper that stirred up so much comment here on Friday. In that post, my first objection (but certainly not my only one) was the chemical structures shown in the paper's Figure 2. Show More Summary

Biology Maybe Right, Chemistry Ridiculously Wrong

A reader sent along a puzzled note about this paper that's out in Science. It's from a large multicenter team (at least nine departments across the US, Canada, and Europe), and it's an ambitious effort to profile 3250 small molecules in a broad chemogenomics screen in yeast. Show More Summary

Encoded Libraries Versus a Protein-Protein Interaction

So here's the GSK paper on applying the DNA-encoded library technology to a protein-protein target. I'm particularly interested in seeing the more exotic techniques applied to hard targets like these, because it looks like there are plenty of them where we're going to need all the help we can get. Show More Summary

The State of Alzheimer's Research, 2014

Via Bernard Munos on Twitter, here's a report from the New York Academy of Sciences looking at the current state of Alzheimer's research. Those various tabs are all live; you can get summaries of each one by clicking. Looking them over breeds a mixture of hope and despair. Show More Summary

AstraZeneca's Cambridge Move

Here's more on AstraZeneca's move to Cambridge (UK). They've set up an agreement with the Medical Research Council to have MRC people working "alongside" AZ people, although details seem pretty short on how that's going to happen in practice. Show More Summary

A Call For Better Mouse Studies

Here's an article by Steve Perrin, at the ALS Therapy Development Institute, and you can tell that he's a pretty frustrated guy. With good reason. That chart shows why. Those are attempted replicates of putative ALS drugs, and you can see that there's a bit of a discrepancy here and there. Show More Summary

Biotech Boom, Biotech Bust?

Here's a good one by Matthew Herper on "Three Misplaced Assumptions That Could End the Biotech Boom". Given the way the biotech stock index has been performing lately, with a horrendous March and April that's taken it into negative territory...Show More Summary

Can You Patent A Natural Product? Prepare For a Different Answer

So, can you patent naturally occurring substances, or not? That's a rather complicated question, and some recent Supreme Court decisions have recomplicated it in US patent law. Mayo v. Prometheus and Assoc. Mol. Pathology v. Myriad Genetics. Show More Summary

Is Palbociclib Promising? Or Not?

Here's a good test for whatever news outlets you might be using for biotech information. How are they handling Pfizer's release of palbociclib information from the AACR meeting over the weekend? Do a news search for the drug's name, and you'll see headline after headline. Show More Summary

Outsourcing Everything

Here's an article in Drug Discovery Today on "virtual pharmaceutical companies", and people who've been around the industry for some years must be stifling yawns already. That idea has been around a long time. The authors here defined...Show More Summary

Cancer Immunotherapy's Growing Pains

Cancer immunotherapy, which I've written about several times here (and which has claimed the constant attention of biopharma investors for some time now) has run into an inevitable difficulty: its patients are very sick, and its effects are very strong. Show More Summary

GSK Dismisses Employees in Bribery Scandal. Apparently.

Someone is letting it be known that GlaxoSmithKline has fired some of its employees in China in relation to the long-running bribery scandal there. This is one of those times when it's worth asking the "Cui bono?" follow-up question....Show More Summary

Copyright © 2011 Regator, LLC